Agios to Present Data From the Phase 3 ClarIDHy Study of TIBSOVO® in Previously Treated IDH1 Mutant Cholangiocarcinoma in Presidential Symposium at ESMO
Agios Pharmaceuticals, Inc. (AGIO)
Last agios pharmaceuticals, inc. earnings: 4/30 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.agios.com/investor-overview
Company Research
Source: GlobeNewswire
CAMBRIDGE, Mass., Sept. 10, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, announces that results from the Phase 3 ClarIDHy study of TIBSOVO® in previously treated IDH1 mutant cholangiocarcinoma have been accepted for presentation in a Presidential Symposium at the European Society for Medical Oncology (ESMO) Annual Meeting being held September 27 – October 1, 2019 in Barcelona. The schedule for the presentation by Agios is as follows: Date & Time: Monday, September 30, 2019 from 4:30 p.m. – 4:42 p.m. CETTitle: ClarIDHy: A global, phase 3, randomized, double-blind study of ivosidenib vs placebo in patients with advanced cholangiocarcinoma with an isocitrate dehydrogenase 1 (IDH1) mutationOral Abstract Session: Presidential Symposium IIIAbstract: LBA10Location: Barcelona Auditorium (Hall 2)Presenter: Ghassan K. Abou-Alfa, Memorial Sloan-Kettering Cancer Center Conference Ca
Show less
Read more
Impact Snapshot
Event Time:
AGIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AGIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AGIO alerts
High impacting Agios Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AGIO
News
- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- https://seekingalpha.com/article/4758644-agios-pharmaceuticals-liver-toxicity-issues-threaten-approval-rating-downgrade [Seeking Alpha]Seeking Alpha
- Agios Pharmaceuticals Inc (AGIO) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and ... [Yahoo! Finance]Yahoo! Finance
- Agios Pharmaceuticals price target lowered to $54 from $55 at BofA [Yahoo! Finance]Yahoo! Finance
- Agios Pharmaceuticals targets multi-billion-dollar growth with Pyrukynd expansion in 2025 [Seeking Alpha]Seeking Alpha
AGIO
Earnings
- 10/31/24 - Miss
AGIO
Sec Filings
- 2/14/25 - Form SCHEDULE
- 2/13/25 - Form 10-K
- 2/13/25 - Form 8-K
- AGIO's page on the SEC website